---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-319156"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:12:15.574366+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics CEO Craig Tooman departs by mutual consent; Chairman Iain Ross named interim CEO

## Summary
- Craig Tooman stepped down as President, CEO and Board member effective Dec 14, 2025 by mutual consent.
- Chairman Iain Ross appointed as interim principal executive officer effective immediately.
- James Ede-Golightly re-appointed to Board; previously served as Non-Executive Director from 2019 to June 2025.
- Company expects to add a US-based Board member in due course.

## SEC filing metadata
- accession: 0001193125-25-319156
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312525319156/0001193125-25-319156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312525319156/sln-20251214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-319156
- JSON: https://secwatch.observer/filing/0001193125-25-319156.json
- Plain text: https://secwatch.observer/filing/0001193125-25-319156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.